Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma

Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma

Neuroblastoma is the most common extra-cranial solid tumor in infants and children, which accounts for approximately 15% of all cancer-related deaths in the pediatric population. New therapeutic modalities are urgently needed. Antibody-Drug Conjugates (ADC)s-based therapy has been proposed as potent...

Full description

Bibliographic Details
Main Authors: Emily Capone, Alessia Lamolinara, Fabio Pastorino, Roberta Gentile, Sara Ponziani, Giulia Di Vittorio, Daniela D’Agostino, Sandra Bibbò, Cosmo Rossi, Enza Piccolo, Valentina Iacobelli, Rossano Lattanzio, Valeria Panella, Michele Sallese, Vincenzo De Laurenzi, Francesco Giansanti, Arturo Sala, Manuela Iezzi, Mirco Ponzoni, Rodolfo Ippoliti, Stefano Iacobelli, Gianluca Sala
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
Antibody-Drug Conjugates (ADC)s
LGALS3BP
neuroblastoma
targeted therapy
Online Access:https://www.mdpi.com/2072-6694/12/10/2989

Internet

https://www.mdpi.com/2072-6694/12/10/2989

Similar Items